BioSci Capital Partners
Contributor since: 2013
Company: Dr. tran biosci
IBI Research On Galapagos: Elucidating The Gilead Mega Deal
Aimmune: Putting The ICER Statement Into Context
Atara: The Silver Bullet For Multiple Sclerosis
Intra-Cellular Therapies: Poised To Rally
Amarin: New Growth Inflection
IBI Daily Market Commentary: Happy July 4th
IBI Daily Market Commentary: Amarin
ImmunoGen: The Comeback Kid
Global Blood Therapeutics: Raining In The Desert With Voxelotor
Atara: Shifting Toward CAR-T
Reata: Blooming With Orphans
Guardant Health: Profiting From Precision Medicine
Avalon Globocare: A Trifecta Biotech
TG Therapeutics: Hitting A Growth Inflection
ArQule: Profiting From Tyrosine Kinase Inhibition
ZioPharm: Awakening Sleeping Beauty CAR-T
Spectrum: Still Opportunistic But Laser Focus
Intercept: Amid The FDA Draft Guidance OCA Will Be Approved
Provention: The Panacea For Diabetes
IBI Top Picks For Summer 2019 Part II: Which Bioscience Stock Will Sit On The Iron Throne?
CRISPR: Vertex Doubled Down On The Reigning Champion CRISPR/Cas9
La Jolla: A Cinderella Bioscience Innovator
Mirati: Brewing A Knock Out Combo Against Cancers
Nektar: Robust Data Presented At ASCO 2019
Genocea: Strong Phase 1/2 Data For GEN-09 Presented At ASCO
IBI Top Picks For Summer 2019 Part I
IBI Research On Axsome: A Flurry Of Powerful Catalysts
IBI Report On Regenxbio: More To Come After Zolgensma Approval
IBI Notable Community Discussion: The Best Is Yet To Come
IBI Research On Verastem: Will Copiktra Saves The Day?
IBI Report On Mallinckrodt: Can This Grower Successfully Turnaround?
IBI Research On Sesen: What Investors Can Expect Going Forward?